Barr’s Videx EC Generic Carries 180-Day Marketing Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved the first ANDA for Bristol’s antiretroviral after completing expedited review under the President’s Emergency Plan for AIDS Relief, Barr says. Expiration of a data exclusivity agreement between Bristol and NIH in May 2004 cleared the way for Barr’s ANDA filing.